American Diabetes Association’s 79th Scientific Sessions to Highlight the Latest Advances in Diabetes Research
World’s largest conference focused on diabetes research, treatment and care to be held
June 7-11, 2019, in San Francisco
WHAT
The American Diabetes Association (ADA) has officially opened online registration for members of the media to its 79th Scientific Sessions, the world’s largest scientific meeting focused on diabetes research, prevention, and care, to be held June 7-11, 2019, at the Moscone Center in San Francisco, California. More than 11,000 leading physicians, scientists, and health care professionals from around the world are expected to convene at the 2019 Scientific Sessions to unveil cutting-edge research, treatment recommendations, and advances toward a cure for diabetes. The Advance Program information outlines speakers, topics, and schedules of the five-day meeting, during which attendees receive exclusive access to more than 2,800 original research presentations and may participate in provocative and engaging exchanges with leading diabetes experts. The program is grouped into eight thematic areas: Acute and Chronic Complications; Behavioral Medicine, Clinical Nutrition, Education, and Exercise; Clinical Diabetes/Therapeutics; Epidemiology/Genetics; Immunology/Transplantation; Insulin Action/Molecular Metabolism; Integrated Physiology/Obesity; and Islet Biology/Insulin Secretion.
WHO
The ADA provides complimentary access to the Scientific Sessions to credentialed members of the media, including print, broadcast, and online media for the express purpose of gathering news and information to produce original news articles about research presented at the 79th Scientific Sessions. Media representatives welcome to attend include reporters, writers, photographers, and videographers. News organizations seeking media credentials must be members of the editorial staff, and media registration is limited to two individuals per outlet/news organization. All press attendees must adhere to the Guidelines for Press and Media.
SESSIONS
In addition to key scientific sessions and award lectures being developed by the Scientific Sessions Meeting Planning Committee, the 79th Scientific Sessions will feature results from the following key clinical trials, presented for the first time, including landmark trials sponsored by the National Institutes of Health:
- The Vitamin D and Type 2 Diabetes (D2d) Study—A Multicenter Randomized Controlled Trial for Diabetes Prevention
- Longitudinal Outcomes in Youth with Type 2 Diabetes—The TODAY2 Study
- Results and Comparisons from the RISE Clinical Trial—Adult Medication Study
- PREVIEW Study Results—Prevention of Diabetes through Lifestyle Intervention and Population Studies Around the Words
- DECLARE-TIMI 58 Trial
- Once-Weekly Dulaglutide and Major Cardiovascular Events—Results of the REWIND Trial
- The CAROLINA Trial—First Results of the Cardiovascular Outcomes Trial Comparing Linagliptin vs. Glimepiride
- CREDENCE and CARMELINA—Results from Two Major Clinical Trials in Kidney and Cardiovascular Disease in Diabetes
- Oral Semaglutide—The PIONEER Program Trials
- Teplizumab for Prevention of Type 1 Diabetes in Relatives “At-Risk”
ADDITIONAL INFO
Scientific research will be highlighted during symposia, mini-symposia, current issues, oral and poster presentations, and Professional Interest Group discussions. The 79th Scientific Sessions also includes presence from more than 100 corporate and organizational exhibitors in over 100,000 square feet of exhibit space. For complete information on the 2019 Scientific Sessions, click here.
Beginning this year, the ADA is taking a tangible step to reduce paper consumption and demonstrate our commitment to the environment. Specifically, the ADA will no longer print the Scientific Sessions Abstract Book or on-site daily newspaper. Both will still be available through the Scientific Sessions meeting app (available free for Apple and Android mobile devices) and online.
Please send an email to the ADA Press Office: SciSessionsPress@diabetes.org if you have any questions.
